Crossmark

Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases

Crossref DOI link: https://doi.org/10.1186/s13023-021-01901-6

Published Online: 2021-06-09

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Miller, Kathleen L. http://orcid.org/0000-0002-3939-3660
Fermaglich, Lewis J.

Maynard, Janet
License Information

Text and Data Mining valid from 2021-06-09

Version of Record valid from 2021-06-09
More Information

Article History

Received: 18 October 2020

Accepted: 29 May 2021

First Online: 9 June 2021

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

: This article reflects the views of the authors and should not be construed to represent FDA’s views or policies.

Document is current

Any future updates will be listed below